Aton Pharma Inc.
This article was originally published in Start Up
Executive Summary
Over the course of two decades, three leading cancer investigators from Memorial Sloan-Kettering Cancer Center (MSKCC), Paul Marks, MD, Richard Rifkind, MD, and Victoria Richon, PhD, along with Ronald Breslow, PhD of Columbia University, have performed research with the objective to develop safer, more effective cancer treatments. Their pioneering work focused on an emerging class of anti-tumor agents-histone deacetylase (HDAC) inhibitors. Now the team of four hopes to translate lab research to drug development in Aton Pharma Inc.
You may also be interested in...
Triggering Transcription: Seemingly Inactive Genes are On, but 'Stuck in Neutral'
Interest in gene regulatory networks is white hot, encompassing topics as wide ranging as reprogramming skin cells to give them characteristics of embryonic stem cells to the successful development of HDAC inhibitors. Now a research team has shown that many important regulatory genes in adult cells aren't switched off, as had been believed. They're primed to make protein, but something is stopping transcription--possibly a set of master signals that could be modulated with small molecules.
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.
What Entrepreneurs Want, Get, and Don't Get from VCs
What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.